Cargando…

Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma

Angiogenesis is a critical step during tumor progression. Anti-angiogenic therapy has only provided modest benefits in delaying tumor progression despite its early promise in cancer treatment. It has been postulated that anti-angiogenic therapy may promote the emergence of a more aggressive cancer c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Shujing, Tetzlaff, Michael T., Wang, Tao, Chen, Xiang, Yang, Ruifeng, Kumar, Suresh M., Vultur, Adina, Li, Pengxiang, Martin, James S., Herlyn, Meenhard, Amaravadi, Ravi, Li, Bin, Xu, Xiaowei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777760/ https://www.ncbi.nlm.nih.gov/pubmed/29383148 http://dx.doi.org/10.18632/oncotarget.22944

Ejemplares similares

PIM kinases as therapeutic targets against advanced melanoma
por: Shannan, Batool, et al.
Publicado: (2016)

NUMB as a Therapeutic Target for Melanoma
por: Hristova, Denitsa M., et al.
Publicado: (2022)

Autophagy Paradox: Strategizing Treatment Modality in Melanoma
por: Pangilinan, Christian, et al.
Publicado: (2023)

Narrowing the knowledge gaps for melanoma
por: Slipicevic, Ana, et al.
Publicado: (2012)

Functional Profiling of Live Melanoma Samples Using a Novel Automated Platform
por: Schayowitz, Adam, et al.
Publicado: (2012)

Gene expression profiling of melanoma cells – searching the haystack
por: Brafford, Patricia, et al.
Publicado: (2005)

The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
por: Desai, Brijal M., et al.
Publicado: (2013)

Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma
por: Bogenrieder, Thomas, et al.
Publicado: (2002)

Patient-derived melanoma organoid models facilitate the assessment of immunotherapies
por: Ou, Lingling, et al.
Publicado: (2023)

Pre-clinical modeling of cutaneous melanoma
por: Rebecca, Vito W., et al.
Publicado: (2020)

Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib
por: Huang, Qiang, et al.
Publicado: (2015)

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression
por: Li, Ling, et al.
Publicado: (2011)

From cancer stem cells to tumor maintenance in melanoma
por: Fukunaga-Kalabis, Mizuho, et al.
Publicado: (2011)

Preclinical platforms to study therapeutic efficacy of human γδ T cells
por: Ou, Lingling, et al.
Publicado: (2022)

Matricellular Proteins Produced by Melanocytes and Melanomas: In Search for Functions
por: Fukunaga-Kalabis, Mizuho, et al.
Publicado: (2008)

Direct conversion of mouse and human fibroblasts to functional melanocytes by defined factors
por: Yang, Ruifeng, et al.
Publicado: (2014)

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
por: Guise, Christopher P., et al.
Publicado: (2014)

Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches
por: Maurer, Margarita, et al.
Publicado: (2012)

Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma
por: Krepler, Clemens, et al.
Publicado: (2016)

Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

From prodrug to pro-prodrug: hypoxia-sensitive antibody–drug conjugates
por: Wang, Yanming, et al.
Publicado: (2022)

Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts
por: Gaustad, Jon-Vidar, et al.
Publicado: (2012)

The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells
por: Stejerean-Todoran, Ioana, et al.
Publicado: (2022)

Resolution of Cullen's sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302
por: Weiss, Glen J., et al.
Publicado: (2011)

Synthesis, Characterization and in vitro Studies of a Cathepsin B‐Cleavable Prodrug of the VEGFR Inhibitor Sunitinib
por: Karnthaler‐Benbakka, Claudia, et al.
Publicado: (2018)

BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression
por: Zeng, Furong, et al.
Publicado: (2023)

Expression of Integrin Alpha10 Is Induced in Malignant Melanoma
por: Wenke, Ann-Kathrin, et al.
Publicado: (2007)

Pro-Invasive Activity of the Hippo Pathway Effectors YAP and TAZ in Cutaneous Melanoma
por: Nallet-Staub, Flore, et al.
Publicado: (2014)

Hypoxia-activated prodrugs and redox-responsive nanocarriers
por: Zeng, Yun, et al.
Publicado: (2018)

Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy
por: Denny, William A.
Publicado: (2022)

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
por: van der Wiel, Alexander M.A., et al.
Publicado: (2021)

TRIM15 and CYLD regulate ERK activation via lysine 63-linked polyubiquitination
por: Zhu, Guixin, et al.
Publicado: (2021)

Therapeutic Potential of Prodrugs Towards Targeted Drug Delivery
por: Mishra, Abhinav P., et al.
Publicado: (2018)

Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population
por: Fukunaga-Kalabis, Mizuho, et al.
Publicado: (2010)

Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
por: Dickson, Benjamin D., et al.
Publicado: (2019)

In vitro radiosensitization of breast cancer with hypoxia‐activated prodrugs
por: Aiyappa‐Maudsley, Radhika, et al.
Publicado: (2022)

Antibody-Based Imaging of Bioreductive Prodrug Release in Hypoxia
por: Tosun, Çağla, et al.
Publicado: (2023)

Editorial: Prodrug design and therapeutic applications
por: Xiao, Qicai, et al.
Publicado: (2023)

Challenges in the humanized mouse model for cancer: A commentary
por: Ramirez-Salazar, Eric, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3luqvgr6r3lb5n24fm5lgi64v6